QRICH1 Drives HBV-Induced HMGB1 Secretion in Hepatic Fibrosis

Study Background and Research Question

Chronic hepatitis B virus (HBV) infection is a leading cause of hepatic fibrosis and cirrhosis, yet the molecular mechanisms bridging viral persistence, hepatocyte stress, and progressive fibrosis remain incompletely understood. High mobility group box 1 (HMGB1), typically a nuclear protein, can act as a damage-associated molecular pattern (DAMP) when secreted, amplifying immune responses and fibrogenesis. Despite evidence implicating extracellular HMGB1 in HBV-related liver pathology, the cellular pathways governing its release during chronic infection have not been fully elucidated. The reference study (Feng et al., 2025) investigates whether glutamine-rich 1 (QRICH1)—a protein upregulated during endoplasmic reticulum (ER) stress—modulates HBV-induced HMGB1 secretion, and if so, by what mechanism.

Key Innovation from the Reference Study

The central innovation lies in identifying QRICH1 as a pivotal link between ER stress and the enhanced translocation and secretion of HMGB1 in hepatocytes during HBV infection. Specifically, the study demonstrates that QRICH1 not only responds to ER stress but actively augments the transcription and acetylation-driven release of HMGB1 in the context of viral hepatitis. This mechanistic insight advances current understanding by situating QRICH1 as a critical effector in the HBV–ER stress–HMGB1 axis, providing a new molecular target for future anti-fibrotic interventions (Feng et al., 2025).

Methods and Experimental Design Insights

The investigators employed a multi-tiered approach encompassing animal models, human clinical specimens, and molecular assays. Key elements of the experimental design included:

• In vivo mouse model: Chronic HBV infection was established using rcccDNA (recombinant covalently closed circular DNA) mice, enabling the study of fibrogenic progression under persistent viral stress.
• Clinical validation: Liver tissue and serum were obtained from patients with chronic hepatitis B and varying degrees of fibrosis, supporting translational relevance.
• Molecular and histological analyses: Immunohistochemistry quantified QRICH1 and HMGB1 expression; Sirius red and Masson’s trichrome staining assessed collagen deposition; ELISA measured serum HMGB1 and liver injury markers.
• Mechanistic assays: Western blotting and qRT-PCR determined HMGB1 cytoplasmic/nuclear distribution and transcriptional regulation; SIRT6 expression and its impact on HMGB1 acetylation were also interrogated.

This integrated design allowed the authors to connect cellular stress pathways with whole-organism and clinical fibrosis phenotypes.

Protocol Parameters

• HBV rcccDNA mouse model | 20–25 g mice | Hepatic fibrosis modeling | Recapitulates human HBV persistent infection and fibrogenesis | paper | DOI
• Immunohistochemistry | DAB staining, 5 μm sections | Protein localization (QRICH1, HMGB1) | Quantitative spatial assessment in liver tissue | paper | DOI
• ELISA for HMGB1 | Serum sample, 100 μL | Quantification of secreted DAMP | Monitors extracellular HMGB1 as fibrosis biomarker | paper | DOI
• Western blot for HMGB1/SIRT6 | 30–50 μg protein | Subcellular translocation and acetylation status | Dissects nuclear/cytoplasmic HMGB1 pools and regulatory enzymes | paper | DOI

Core Findings and Why They Matter

The study’s major findings are as follows:

• ER stress drives HBV-induced hepatic fibrosis: Both mouse and human data demonstrate that ER stress markers, including QRICH1, are elevated in fibrotic livers during chronic HBV infection, correlating with increased HMGB1 secretion (Feng et al., 2025).
• QRICH1 is essential for HMGB1 translocation and secretion: Upregulation of QRICH1 enhances the transcription of HMGB1 and promotes its nuclear export and release, amplifying the profibrogenic DAMP signal.
• HBV modulates SIRT6 to promote HMGB1 acetylation: HBV infection suppresses SIRT6, a deacetylase, thereby facilitating HMGB1 acetylation and its cytoplasmic translocation—a prerequisite for secretion.
• QRICH1 and HMGB1 are positively correlated in clinical fibrosis: Patient samples confirm the experimental findings, with higher QRICH1 and HMGB1 expression in more advanced hepatic fibrosis.

These results clarify a previously underappreciated axis—HBV/QRICH1/ER stress—that orchestrates HMGB1-driven inflammation and fibrosis. By identifying QRICH1 as a molecular amplifier, the work supports the rationale for targeting ER stress effectors in anti-fibrotic therapy.

Comparison with Existing Internal Articles

Several recent internal resources contextualize the broader significance of ER stress, insulin signaling, and metabolic regulation in advanced disease models:

• "Bovine Insulin Beyond the Bench" explores the mechanistic crosstalk between insulin signaling, ER stress, and metabolic rewiring, highlighting how peptide hormones such as insulin from bovine pancreas can be leveraged for in vitro models of stress response and fibrosis.
• "Bovine Insulin as a Translational Engine" frames bovine insulin as a growth factor supplement for cultured cells that can modulate mitochondrial and fibrogenic pathways, providing an experimental foundation for studies of metabolic disease, cell proliferation enhancement, and hepatic injury.

While these internal articles focus on insulin signaling and cell culture applications, the current reference study deepens the mechanistic landscape by pinpointing QRICH1 as a crucial ER stress effector in the context of viral hepatitis and fibrotic remodeling. For researchers modeling ER stress or insulin signaling pathway dynamics, the synergy between these themes supports the use of optimized cell culture systems to dissect molecular drivers of fibrosis or metabolic disease.

Limitations and Transferability

Despite its strengths, the study has several limitations:

• Species and model specificity: The rcccDNA mouse model provides a robust platform for studying chronic HBV infection, but it may not fully recapitulate the complexity of human hepatic fibrosis, especially regarding immune cell diversity and long-term disease progression [workflow_recommendation].
• Focus on QRICH1 in hepatocytes: While the study emphasizes QRICH1’s role in hepatocytes, the contribution of non-parenchymal liver cells (e.g., hepatic stellate cells, Kupffer cells) to ER stress and fibrogenesis warrants further investigation [workflow_recommendation].
• Therapeutic translation: Although QRICH1 emerges as a promising target, direct modulation of this pathway in human patients requires additional preclinical validation [workflow_recommendation].

The mechanistic insights are most readily transferable to in vitro and animal models for dissecting ER stress, DAMP signaling, and fibrogenic responses, with careful consideration of model-specific constraints.

Why this cross-domain matters, maturity, and limitations

The connection between viral infection, ER stress, and fibrogenic signaling is well-established in hepatic research. This cross-domain bridge—spanning virology, immunology, and fibrosis—is mature in animal and in vitro systems but remains underexplored in clinical intervention. The reference study advances conceptual maturity by clarifying QRICH1’s mechanistic position, though translational gaps remain in targeting this pathway therapeutically [source_type: paper | source_link: https://doi.org/10.1016/j.imbio.2025.152913].

Research Support Resources

For researchers modeling ER stress, insulin signaling, or fibrogenic responses in cultured cells, the choice of growth factor supplement can impact reproducibility and physiological relevance. Bovine Insulin (SKU A5981) from APExBIO is a high-purity, well-characterized peptide hormone derived from bovine pancreas, commonly used to promote cell proliferation and regulate glucose metabolism in vitro [source_type: product_spec | source_link: https://www.apexbt.com/bovine-insulin.html]. Its solubility profile (≥10.26 mg/mL in DMSO with ultrasonic assistance) and accompanying documentation make it suitable for advanced cell culture models investigating metabolic and stress pathways. While not directly tested in the reference study, Bovine Insulin serves as a relevant cell proliferation enhancer and metabolic modulator for in vitro experiments that parallel the mechanistic themes outlined above. Researchers are advised to consult workflow recommendations and product specifications for optimal usage.